JAK1 and COVID-19: Baricitinib inhibits Janus kinase 1/2 (JAK1/2), which is essential, although not restricted, to IFNAR signaling (59), and early evaluation in combination with remdesivir in hospitalized patients with COVID-19 yielded promising results, with significantly reduced mortality (60).